Insight Molecular Diagnostics
IMDX
40 hedge funds and large institutions have $109M invested in Insight Molecular Diagnostics in 2026 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 13 closing their positions.
75% more capital invested
Capital invested by funds: $62.1M → $109M (+$46.8M)
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1.69% less ownership
Funds ownership: 58.87% → 57.18% (-1.7%)
2% less funds holding
Funds holding: 41 → 40 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$3.72M |
| 2 |
FOR
Family Office Research
Bethesda,
Maryland
|
+$1.19M |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$981K |
| 4 |
Jane Street
New York
|
+$778K |
| 5 |
State Street
Boston,
Massachusetts
|
+$204K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.76M |
| 2 |
PVI
Pura Vida Investments
New York
|
-$2.28M |
| 3 |
HCM
Heights Capital Management
San Francisco,
California
|
-$1.29M |
| 4 |
FIA
FNY Investment Advisers
New York
|
-$320K |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$232K |
IMDX Hedge Fund Activity: Q2 2026 in Review
40 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2026, worth a combined $109M — up 75% from $62.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of IMDX and 12 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 10 added.
The largest buyer was Broadwood Capital, adding an estimated $3.72M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $2.76M sold.
- 40 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2026, down from 41 in Q1 2026.
- Funds reported $109M of Insight Molecular Diagnostics stock for Q2 2026, up 75% quarter-over-quarter.
- 12 funds opened new Insight Molecular Diagnostics positions in Q2 2026 and 13 closed out, a net change of -1 holder.
- The largest Insight Molecular Diagnostics buyer in Q2 2026 was Broadwood Capital, an estimated $3.72M added.
- The largest Insight Molecular Diagnostics seller in Q2 2026 was Alyeska Investment Group, an estimated $2.76M sold.
Based on aggregated 13F filings for Q2 2026.